The ERBB2 gene, also known as HER2, is a key player in cell growth and division. It codes for a protein called human epidermal growth factor receptor 2, which is a type of receptor tyrosine kinase. This protein is involved in stimulating cell growth, development, and repair. However, when the ERBB2 gene becomes mutated or overexpressed, it can lead to uncontrolled cell growth, which is a characteristic of cancer. The ERBB2 gene is often amplified or mutated in various types of cancers, such as breast, ovarian, and stomach cancers. Targeting the ERBB2 gene and its protein product has become a crucial strategy in the treatment of these cancers, leading to improved patient outcomes.
The T47D cell line is a human breast cancer cell line that was established from a patient with ductal carcinoma in situ. This cell line has been extensively used in research to study the biology of breast cancer and to develop and test new therapeutic agents. The T47D cells have been found to have high expression of the ERBB2 gene, making them a valuable model for studying the role of ERBB2 in breast cancer progression and for evaluating the effectiveness of anti-ERBB2 therapies. The T47D cells have also been used to study other aspects of breast cancer, such as the role of other genetic factors and the response to different types of chemotherapy.
Emphasizing the important function of Nectin-4 in cancer, it is well known that this protein interacts with ErbB2, a major factor in the development of breast cancer, and is elevated in many other malignancies. To look at the cooperative impact of Nectin-4 and ErbB2, the researchers used human breast cancer T47D cells endogenously expressing both of these proteins. They specifically examined how the combination of Nectin-4 and p95-ErbB2 enhances SOX2 gene expression and promotes cell proliferation in suspension culture. Their findings indicated that this cooperation activates the PI3K-AKT signaling pathway, a crucial mechanism for cell growth. By establishing various stable T47D cell lines expressing different combinations of ErbB2 and Nectin-4, they were able to quantify the proliferation rates under anchorage-independent conditions.
Figure 1. The researchers cultured T47D cells in RPMI-1640 medium and employed electroporation to introduce plasmids for stable expression of Nectin-4 and ErbB2, aiming to investigate their roles in enhancing cell proliferation and SOX2 expression. (Kedashiro S, et al., 2021)
The ERBB2 gene, also known as HER2, encodes a protein called human epidermal growth factor receptor 2, a receptor tyrosine kinase. This protein is involved in cell growth, proliferation, and differentiation. abnormalities in the ERBB2 gene lead to overexpression of the HER2 protein, which is commonly associated with the development of various cancers such as breast, gastric, and ovarian cancers.
Targeting the ERBB2 gene and its protein products has become a key strategy for the treatment of HER2-positive cancers. The development of targeted therapies such as monoclonal antibodies that specifically bind to the HER2 protein (e.g., trastuzumab) and small molecule inhibitors that block the activity of the HER2 protein has greatly improved the prognosis of patients with HER2-positive cancers.
In addition to its role in cancer therapy, the ERBB2 gene is an important biomarker for predicting prognosis and guiding the treatment of patients with various types of cancer. For example, overexpression or amplification of the HER2 gene can be used to identify patients who are more likely to benefit from targeted therapies.
In summary, the ERBB2 gene and its protein products play a critical role in cell growth and proliferation, and their aberrations have been linked to the development of various types of cancer. Targeting the ERBB2 gene and its protein products has emerged as an important strategy for the treatment and management of HER2-positive cancers, improving patient prognosis and providing valuable biomarkers for prognostic and therapeutic guidance.
Customer Reviews
Precision of gene editing
The Human ERBB2 Stable Cell Line-T47D is crafted with high precision, ensuring specific and targeted modifications to the ERBB2 gene. This accuracy is crucial for studying the function of ERBB2 in cancer development and testing potential therapeutic interventions.
Persistence of modifications
The genetic modifications in the Human ERBB2 Stable Cell Line-T47D are designed to be stable over numerous cell divisions, providing a consistent and reliable model for long-term experiments. This durability is essential for researchers conducting extended studies on ERBB2-related biology.
Adaptability for large-scale research
The Human ERBB2 Stable Cell Line-T47D is well-suited for large-scale research projects, as it can be easily expanded and maintained in culture. This scalability allows researchers to perform high-throughput screens, molecular analyses.
Cost-effectiveness
The Human ERBB2 Stable Cell Line-T47D offers a cost-effective solution for researchers, as it eliminates the need for frequent gene editing and cell line generation. The stable nature of this cell line reduces costs associated with reagents, labor, and time, making it an efficient choice for ERBB2-related research.
Write a Review